Covid-19 roundup: With ef­fi­ca­cy da­ta in hand, BioN­Tech talks pric­ing; Brazil halts Sino­vac tri­al fol­low­ing pa­tient death

On the heels of be­com­ing the first to re­lease Phase III ef­fi­ca­cy da­ta for the Covid-19 vac­cine it de­vel­oped with Pfiz­er, BioN­Tech is now talk­ing pric­ing.

BioN­Tech CSO Ryan Richard­son said at a Fi­nan­cial Times vir­tu­al event that the com­pa­ny is aim­ing to set a price point be­low “typ­i­cal mar­ket rate” for its two-shot vac­cine, per Reuters. The firm al­so ex­pects the price will be dif­fer­ent de­pend­ing on the coun­try or re­gion in which it’s sold, though Richard­son did not elab­o­rate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER